A major new insight into how Hepatitis B virus works could pave the way for new drug treatments for the infection, which is the major cause of liver cancer worldwide.
The team at the Universities of York and Leeds identified an “assembly code” in the genetic material of Hepatitis B virus that allows it to create a protective casing in which it can produce new infectious virus particles.
They found that the signal, generated by ribonucleic acid (RNA), helps viral proteins to overcome an ‘engineering problem’, assembling them into in a particular geometric pattern.
Professor Reidun Twarock, mathematical biologist at the University of York’s Department of Mathematics and Biology, said: “It is a bit like the chain on a bicycle. If we don’t assemble the chain on the sprockets, it becomes tangled and won’t function. Once assembled correctly, it connects the pedals with the wheels allowing the component parts to work together.
“We see the same process happening between the Hepatitis B RNA signals and the viral proteins. The proteins are attracted by these signals, which then promote their assembly into a precise molecular machine that allows the virus to produce a DNA copy of its genetic material and hence become infectious.”
The virus is transmitted through blood and bodily fluids. It is thought that more than two billion people have been infected worldwide, and around 350 million people remain carriers of the infection, which can, over time, result in their deaths.
The virus occurs in Europe but is much more common in parts of Asia, especially China and Africa. There are more than one million infected people in the USA where treatments can include expensive drugs and even liver transplantation.
Professor Peter Stockley, a structural virologist from the University of Leeds Astbury Centre, said: “There is a vaccine for the virus, but once you have the condition there is no treatment, other than drugs that can reduce symptoms but not change the long-term outlook.
“We often compare the disease to HIV due to the way in which the virus is passed from person-to-person, but unlike HIV there are no effective drugs to improve quality of life outcomes. Now that we know how the virus assembles, we can interrupt the interactions with the RNA signals – a bit like when a twig catches the sprocket on a bike, knocking the chain off.”
The Latest on: Hepatitis B
- Lexington hepatitis A cases double in one month. Vaccinations advised for all residents. on October 5, 2018 at 10:02 am
The amount of hepatitis A cases in Lexington more than doubled in one month, according to new data supplied from the Lexington-Fayette County Health Department. Lexington had 13 confirmed hepatitis A ... […]
- J&J Unit Strikes $3.7B Hepatitis B Gene Therapy Deal on October 4, 2018 at 9:45 am
Law360 (October 4, 2018, 12:38 PM EDT) -- Johnson & Johnson subsidiary Janssen Pharmaceuticals Inc. on Thursday struck a deal with Arrowhead Pharmaceuticals Inc. worth as much as $3.7 billion to help ... […]
- Agreement expands breadth of Janssen’s hepatitis B virus development portfolio on October 4, 2018 at 8:53 am
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that Janssen Pharmaceuticals, Inc., (Janssen) has entered into an agreement with Arrowhead Pharmaceuticals, Inc., (Arrowhead) ... […]
- J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion on October 4, 2018 at 5:16 am
(Reuters) - Arrowhead Pharmaceuticals Inc (ARWR.O) said on Thursday Johnson & Johnson (JNJ.N) would develop and market its gene-silencing Hepatitis B drug and pick up a minor stake in the company ... […]
- Hepatitis B Therapeutics Market Forecast to 2025 insights shared in detailed report on October 4, 2018 at 2:37 am
Hepatitis B Therapeutics Market top manufacturers covered in report- GlaxoSmith Kline, Bristol-Myers Squibb, Novira Therapeutics, Johnson & Johnson, Abivax, F. Hoffmann- La Roche, Novartis, Merck In 2... […]
- Globe-trotting decision scientist seeks solutions to hepatitis B on October 2, 2018 at 12:27 pm
Mehlika Toy merged her interests in infectious diseases and mathematics to forge a career in decision science. She builds models to estimate the impact of clinical interventions to inform health polic... […]
- What’s the Difference Between Hepatitis A, B, and C (and Should You Be Worried About Hepatitis E)? on October 2, 2018 at 11:53 am
You’ve heard of hepatitis — and you know there are varying types –but when it comes to the facts, how much do you really know? The World Health Organization reminds us at its core, hepatitis is simply ... […]
- Global Hepatitis B Diagnostic Tests Market Detailed Analysis by Types & Applications with Key Companies Profile on September 29, 2018 at 12:29 am
(EMAILWIRE.COM, September 29, 2018 ) Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Hepatitis B ... […]
- This Disease Is A Top Killer And Now States Must Pay For Its Costly Treatment on September 25, 2018 at 8:39 am
a coalition working to eradicate hepatitis B and C. Kellie Wasko, deputy executive director at the Colorado Department of Corrections, said the settlement the state reached with the American Civil Lib... […]
- Officials warn Masaka schools on Hepatitis B vaccination on September 24, 2018 at 4:11 pm
In March, the Ministry of Health halted private players from administering Hepatitis B vaccination and testing after some private health facilities were feared to offer fake vaccines to the desperate ... […]
via Google News and Bing News